Envista (NVST)
(Delayed Data from NYSE)
$19.41 USD
+0.74 (3.96%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $19.40 -0.01 (-0.05%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.41 USD
+0.74 (3.96%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $19.40 -0.01 (-0.05%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth F Momentum B VGM
Zacks News
Envista (NVST) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of 20.46% and 4.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth (CGC) to Report in Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal first quarter.
Envista (NVST) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
7 Low Price-to-Book Stocks to Add to Your Kitty
by Kinjel Shah
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
Medtronic (MDT) Introduces New Drug Coated Balloon Catheter
by Zacks Equity Research
Medtronic's (MDT) newly-launched Prevail DCB demonstrates impressive safety and drug deliverability, utilizing a rapid absorption drug to treat patients with coronary artery disease.
Omnicell (OMCL) Faces Lingering Cost Woes, Fierce Competition
by Zacks Equity Research
Omnicell's (OMCL) second-quarter 2021 guidance includes additional freight costs, given the ongoing global market conditions.
NuVasive (NUVA) Launches Modulus ALIF for Anterior Spine Surgery
by Zacks Equity Research
The Modulus ALIF 3D-printed porous titanium implant is the latest addition to NuVasive's (NUVA) AMS portfolio for anterior lumbar interbody fusion procedures.
Medtronic's (MDT) Hugo RAS System Now Available at UC CHRISTUS
by Zacks Equity Research
Recent integration of Medtronic's (MDT) Hugo RAS System at UC CHRISTUS is intended to support the teaching institution's new robotic surgery program.
Quest Diagnostics (DGX) Expands Testing Access With CLX Pact
by Zacks Equity Research
Quest Diagnostics' (DGX) COVID-19 testing will be available through TrustAssure platform for international travelers and live event attendants.
NVST vs. PETQ: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVST vs. PETQ: Which Stock Is the Better Value Option?
Cerner (CERN) Extends Partnership to Accelerate Digital Health
by Zacks Equity Research
Cerner (CERN) expands its partnership with Baystate Health by launching a digital health platform to boost consumer-focused care.
Integra (IART) Releases Favorable PriMatrix Clinical Outcome
by Zacks Equity Research
Integra's (IART) PriMatrix study data validates that one application of PriMatrix is needed to address hard-to-heal diabetic foot ulcers.
Thermo Fisher (TMO) Advances Customer Research With New Launch
by Zacks Equity Research
Thermo Fisher's (TMO) new instrument enables high-resolution images of nanoparticles and beam-sensitive materials to be obtained from a commercially available desktop SEM.
Globus Medical (GMED) Marks New Milestone for ExcelsiusGPS
by Zacks Equity Research
Globus Medical's (GMED) ExcelsiusGPS Robotic Navigation system reaches new surgical milestone for spinal procedures.
Thermo Fisher (TMO) to Meet Plasmid DNA Demand With New Facility
by Zacks Equity Research
Thermo Fisher's (TMO) new facility will manufacture materials that are essential for production of plasmid-based therapies and vaccines.
National Vision (EYE) Banks on Partnerships Amid COVID-19 Woes
by Zacks Equity Research
National Vision (EYE) is confident about its financial flexibility and liquidity helping it to navigate this pandemic.
Integra's (IART) SurgiMend Gets Innovative Technology Contract
by Zacks Equity Research
Integra's (IART) SurgiMend Collagen Matrix is recognized as a product that can potentially bring improvement to the health care industry.
Fresenius Medical's (FMS) Xenios Gets NMPA Nod for ECMO System
by Zacks Equity Research
Fresenius Medical (FMS) company receives expedited approval from NMPA permitting the Xenios AG's console and patient kits for ECMO therapy in China.
Here's Why You Should Retain Avanos (AVNS) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Hologic (HOLX) COVID Test With Saliva Sample Gets CE Mark
by Zacks Equity Research
Per Hologic (HOLX), saliva collection is noninvasive and painless. The availability of this alternative specimen type should facilitate screening at schools, workplaces and other settings.
Orthofix's (OFIX) SpinalStim Demonstrates Improved Fusion Rates
by Zacks Equity Research
Orthofix's (OFIX) SpinalStim bone growth device demonstrates impressive fusion rates for patients recovering from lumbar fusion surgery.
Stryker (SYK) Unveils Tornier Shoulder Arthroplasty Portfolio
by Zacks Equity Research
Stryker (SYK) introduces new Tornier shoulder arthroplasty portfolio enabling the company to strengthen its position in the shoulder market.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from robust payment accuracy business. However, intense competition remains a woe.
Thermo Fisher's (TMO) New Pact Drives Sustainable Lab Practices
by Zacks Equity Research
Thermo Fisher (TMO) expects to ACT label more than 1,200 additional SKUs to allow research, pharmaceutical and clinical laboratories to achieve their sustainability objectives.
QIAGEN (QGEN) Stock Falls on Downbeat Full-Year Guidance
by Zacks Equity Research
According to QIAGEN (QGEN), stronger-than-expected growth trends were seen in non-COVID product groups in the second quarter of 2021.